EGFR and non-small cell lung carcinoma: Firstly, it highlighted the prevailing trend in clinical practice where the majority of patients with unresectable stage III EGFR-mutated NSCLC were primarily treated with TKI monotherapy, as opposed to chemoradiotherapy.